NZ709620A - Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid - Google Patents
Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroidInfo
- Publication number
- NZ709620A NZ709620A NZ709620A NZ70962014A NZ709620A NZ 709620 A NZ709620 A NZ 709620A NZ 709620 A NZ709620 A NZ 709620A NZ 70962014 A NZ70962014 A NZ 70962014A NZ 709620 A NZ709620 A NZ 709620A
- Authority
- NZ
- New Zealand
- Prior art keywords
- corticosteroid
- insoluble
- soluble
- injection
- intra
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000002347 injection Methods 0.000 abstract 3
- 239000007924 injection Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000005111 ocular hyperemia Diseases 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361755723P | 2013-01-23 | 2013-01-23 | |
| US201361776617P | 2013-03-11 | 2013-03-11 | |
| PCT/US2014/012824 WO2014116876A1 (en) | 2013-01-23 | 2014-01-23 | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ709620A true NZ709620A (en) | 2020-07-31 |
Family
ID=50097866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ709620A NZ709620A (en) | 2013-01-23 | 2014-01-23 | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9833460B2 (enExample) |
| EP (1) | EP2948182B1 (enExample) |
| JP (1) | JP6215354B2 (enExample) |
| KR (1) | KR102055937B1 (enExample) |
| CN (1) | CN105073138B (enExample) |
| AU (2) | AU2014209346B2 (enExample) |
| BR (1) | BR112015017246B1 (enExample) |
| CA (1) | CA2897467C (enExample) |
| IL (1) | IL239791B (enExample) |
| MX (1) | MX366654B (enExample) |
| NZ (1) | NZ709620A (enExample) |
| TW (1) | TWI624262B (enExample) |
| WO (1) | WO2014116876A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0610308A8 (pt) | 2005-05-26 | 2017-04-25 | Neuron Systems Inc | Composições e métodos para o tratamento de doença retinal |
| US9814701B2 (en) | 2009-12-11 | 2017-11-14 | Aldeyra Therapeutics, Inc. | Compositions and methods for the treatment of macular degeneration |
| JP6215354B2 (ja) | 2013-01-23 | 2017-10-18 | セムヌール ファーマシューティカルズ， インコーポレイテッド | 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物 |
| CN105120866B (zh) | 2013-01-23 | 2020-02-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| TWI772659B (zh) * | 2015-01-21 | 2022-08-01 | 美商桑紐爾製藥公司 | 醫藥配方 |
| US11857554B2 (en) | 2015-06-02 | 2024-01-02 | Intravital Pty Ltd. | Drug delivery device with pre-assembled cartridge |
| WO2017035077A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| CA3022665A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| US12006298B2 (en) | 2018-08-06 | 2024-06-11 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| JP2022511030A (ja) * | 2018-12-05 | 2022-01-28 | アルデイラ セラピューティクス， インコーポレイテッド | 注射可能な製剤 |
| CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| US11382863B2 (en) * | 2020-03-04 | 2022-07-12 | Somerset Therapeutics Llc | Injectable suspension comprising an insoluble corticosteroid and a soluble corticosteroid |
| EP4149470A4 (en) | 2020-05-13 | 2024-04-24 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| CA3199093A1 (en) * | 2020-10-22 | 2022-04-28 | Pfizer Inc. | Peg-free aqueous suspensions for parenteral administration of a corticosteroid |
| WO2024159191A1 (en) * | 2023-01-26 | 2024-08-02 | Insignia Pharmaceuticals, Llc | Pharmaceutical compositions for treating osteoarthritis |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL25251A (en) | 1965-07-20 | 1969-11-12 | Merck & Co Inc | Aqueous mixtures for ophthalmology based on hydroxyethylcellulose and a method for their preparation |
| US3962430A (en) * | 1974-08-07 | 1976-06-08 | Merck & Co., Inc. | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride |
| US4304765A (en) | 1980-10-14 | 1981-12-08 | Alza Corporation | Ocular insert housing steroid in two different therapeutic forms |
| EP0244178A3 (en) | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
| IL80298A (en) | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
| FI105075B (fi) | 1996-01-10 | 2000-06-15 | Suprakort Oy | Kombinaatioinjektiovalmisteen käyttö |
| IT1288290B1 (it) | 1996-06-21 | 1998-09-11 | Fidia Spa In Amministrazione S | Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie |
| JPH11279065A (ja) | 1998-03-25 | 1999-10-12 | Shiseido Co Ltd | 局所投与炎症治療剤 |
| US6921532B1 (en) * | 2000-06-22 | 2005-07-26 | Spinal Restoration, Inc. | Biological Bioadhesive composition and methods of preparation and use |
| US6747090B2 (en) * | 2001-07-16 | 2004-06-08 | Pharmacia Groningen Bv | Compositions capable of forming hydrogels in the eye |
| US20040006052A1 (en) | 2002-04-15 | 2004-01-08 | Gudas Charles J. | Injection solutions to treat neuropathic symptoms and other sensorimotor disorders that are due to neuromas of the foot or other entrapment neuropathies of peripheral nerves, and method of use |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050186229A1 (en) | 2004-02-24 | 2005-08-25 | Emmett Clemente | Pleasant-tasting aqueous liquid composition of prednisolone sodium phosphate |
| JP2007001926A (ja) * | 2005-06-24 | 2007-01-11 | Ltt Bio-Pharma Co Ltd | 吸入・噴霧用ステロイド製剤 |
| JP4969812B2 (ja) | 2005-07-22 | 2012-07-04 | 久光製薬株式会社 | ハイドロゲル組成物 |
| US20070099882A1 (en) * | 2005-10-27 | 2007-05-03 | Gurney Harry C | Methods and compositions for prolonged alleviation of articular joint pain |
| EP1968614A2 (en) | 2005-12-14 | 2008-09-17 | Anika Therapeutics Inc. | Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid |
| US20070141160A1 (en) * | 2005-12-15 | 2007-06-21 | Brown Laura J | Method of treatment for osteoarthritis by local intra-articular injection of microparticles |
| CN100534434C (zh) * | 2006-05-15 | 2009-09-02 | 西安力邦制药有限公司 | 透明质酸钠地塞米松脂肪乳制剂及其应用 |
| US20080317805A1 (en) | 2007-06-19 | 2008-12-25 | Mckay William F | Locally administrated low doses of corticosteroids |
| US9421356B2 (en) * | 2007-08-28 | 2016-08-23 | Teikoku Pharma Usa, Inc. | Transdermal methods and systems for the delivery of corticosteroid compounds |
| US20090143348A1 (en) | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
| US20090143807A1 (en) | 2007-12-03 | 2009-06-04 | Vertos Medical, Inc., A Delaware Corporation | Percutaneous Devices for Separating Tissue, Kits and Methods of Using the Same |
| BRPI0905078A2 (pt) * | 2008-04-18 | 2015-06-30 | Medtronic Inc | Métodos para tratar hérnia de disco intervertebral e para reduzir o tamanho de uma hérnia de disco intervertebral, e, depósito implantável de drogas |
| MX2010012397A (es) | 2008-05-14 | 2011-03-15 | Otonomy Inc Star | Composiciones de corticosteroides de liberacion controlada y metodos para el tratamiento de transtornos oticos. |
| WO2010054356A1 (en) * | 2008-11-10 | 2010-05-14 | Nitric Biotherapeutics, Inc. | Pharmaceutical formulations for iontophoretic delivery of a corticosteroid |
| US8790702B2 (en) * | 2009-07-30 | 2014-07-29 | Carbylan Therapeutics, Inc. | Modified hyaluronic acid polymer compositions and related methods |
| UA111162C2 (uk) * | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
| RU2459615C1 (ru) | 2011-03-05 | 2012-08-27 | Илья Александрович Марков | Глазные капли для лечения болезни сухого глаза |
| MX2014006056A (es) | 2011-12-06 | 2014-08-08 | Alcon Res Ltd | Composicion de gel de celulosa con una mejor estabilidad de la viscosidad. |
| US20130165419A1 (en) | 2011-12-21 | 2013-06-27 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
| JP6215354B2 (ja) | 2013-01-23 | 2017-10-18 | セムヌール ファーマシューティカルズ， インコーポレイテッド | 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物 |
| TWI772659B (zh) | 2015-01-21 | 2022-08-01 | 美商桑紐爾製藥公司 | 醫藥配方 |
-
2014
- 2014-01-23 JP JP2015553933A patent/JP6215354B2/ja active Active
- 2014-01-23 WO PCT/US2014/012824 patent/WO2014116876A1/en not_active Ceased
- 2014-01-23 TW TW103102506A patent/TWI624262B/zh active
- 2014-01-23 KR KR1020157022624A patent/KR102055937B1/ko active Active
- 2014-01-23 CN CN201480005642.9A patent/CN105073138B/zh active Active
- 2014-01-23 MX MX2015009455A patent/MX366654B/es active IP Right Grant
- 2014-01-23 US US14/162,625 patent/US9833460B2/en active Active
- 2014-01-23 BR BR112015017246-6A patent/BR112015017246B1/pt active IP Right Grant
- 2014-01-23 CA CA2897467A patent/CA2897467C/en active Active
- 2014-01-23 AU AU2014209346A patent/AU2014209346B2/en active Active
- 2014-01-23 EP EP14704239.4A patent/EP2948182B1/en active Active
- 2014-01-23 NZ NZ709620A patent/NZ709620A/en unknown
-
2015
- 2015-07-05 IL IL239791A patent/IL239791B/en active IP Right Grant
-
2017
- 2017-10-30 US US15/798,053 patent/US10744144B2/en active Active
-
2019
- 2019-01-31 AU AU2019200649A patent/AU2019200649B2/en active Active
-
2020
- 2020-07-06 US US16/921,628 patent/US11364251B2/en active Active
-
2022
- 2022-05-11 US US17/741,729 patent/US12016867B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ709620A (en) | Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid | |
| MX2021012029A (es) | Composicion farmaceutica de corticosteroide soluble. | |
| NZ712350A (en) | Abiraterone acetate formulation | |
| PH12017501774A1 (en) | Compositions comprising a combination of an anti-pd-1 antibody and another antibody | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| PH12015502621A1 (en) | Estrogen receptor modulator and uses thereof | |
| MX357496B (es) | Moduladores del receptor de estrógenos fluorados y sus usos. | |
| MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
| EP3072506A4 (en) | Carrier for drug delivery and conjugate, composition containing same, and method for administering same | |
| MX2015000337A (es) | Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles. | |
| MX2013005621A (es) | Composicion para administracion de farmaco biodegradable. | |
| PH12015501096A1 (en) | Composition for immediate and extended release | |
| WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
| MX2015008021A (es) | Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos. | |
| PH12015501982A1 (en) | Pharmaceutical compositions comprising everolimus | |
| PH12014502571A1 (en) | Ophthalmic compositions with improved dessication protection and retention | |
| EP4233896A3 (en) | Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells | |
| MX2019015527A (es) | Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. | |
| WO2014107596A8 (en) | Compositions and methods for polynucleotide transfection | |
| MX2022012075A (es) | Formulaciones de farmacos de moleculas peque?as resistentes a precipitacion. | |
| MY195509A (en) | Pharmaceutical Formulations for Sustained Release of Sebacoyl Dinalbuphine Ester | |
| MX2018014790A (es) | Formulacion combinada de tres compuestos antivirales. | |
| MX2018009739A (es) | La administración combinada de un agente de penetración y un compuesto que contiene azufre a plantas. | |
| MX2020007270A (es) | Formulacion parenteral que comprende siponimod. | |
| WO2019104062A8 (en) | Polymorphs and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2022 BY CPA GLOBAL Effective date: 20201211 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2023 BY CPA GLOBAL Effective date: 20211210 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2024 BY CPA GLOBAL Effective date: 20221209 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2025 BY CPA GLOBAL Effective date: 20231207 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241212 |